Spyre Therapeutics
SYRE
153 hedge funds and large institutions have $2.65B invested in Spyre Therapeutics in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 76 increasing their positions, 27 reducing their positions, and 14 closing their positions.
553% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $2.24M
500% more funds holding in top 10
Funds holding in top 10: 1 → 6 (+5)
181% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 27
146% more capital invested
Capital invested by funds: $1.08B → $2.65B (+$1.57B)
114% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 14
12% more funds holding
Funds holding: 137 → 153 (+16)
2.09% less ownership
Funds ownership: 106.45% → 104.36% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$67.4M |
| 2 |
PA
Perceptive Advisors
New York
|
+$48.1M |
| 3 |
Janus Henderson Group
London,
|
+$47.5M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$42.4M |
| 5 |
BlackRock
New York
|
+$40.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$34.2M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$24.7M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$23.3M |
| 4 |
Millennium Management
New York
|
-$8.68M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$7.95M |
SYRE Hedge Fund Activity: Q4 2025 in Review
153 of the 8,265 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2025, worth a combined $2.65B — up 146% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SYRE positions and 14 closed out — a net gain of 16 holders — while 76 added to existing stakes and 27 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $67.4M. The largest seller was Tang Capital Management, cutting an estimated $34.2M.
- 153 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2025, up from 137 in Q3 2025.
- Funds reported $2.65B of Spyre Therapeutics stock for Q4 2025, up 146% quarter-over-quarter.
- 30 funds opened new Spyre Therapeutics positions in Q4 2025 and 14 closed out, a net change of +16 holders.
- The largest Spyre Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $67.4M added.
- The largest Spyre Therapeutics seller in Q4 2025 was Tang Capital Management, an estimated $34.2M sold.
Based on aggregated 13F filings for Q4 2025.